This case involves SSL Services, LLC suing Citrix Systems, Inc. and Citrix Online, LLC for allegedly infringing two patents related to virtual private networks (VPNs) that enable secure file transmission over the Internet using authentication and encryption protocols. The court conducted a claim construction hearing to interpret disputed terms in the patents, such as those describing "function calls and requests for service" and their relation to encryption functions in the context of multi-tier VPNs involving client computers and servers. The court decided that several phrases required no construction as their ordinary meaning was clear, while adopting constructions that aligned with the patent specifications and prosecution history without imposing additional limitations like requiring "ordinary" or "unmodified" calls. The reasoning focused on the explicit claim language, the patents' descriptions of shims intercepting calls to generate session keys, and statements made during patent prosecution that did not further restrict the scope as argued by defendants.
This consolidated Hatch-Waxman case involved Allergan suing generic manufacturers Sandoz, Alcon, Apotex, and Watson, who sought FDA approval to market generic versions of Combigan eye drops for treating glaucoma and ocular hypertension. Allergan alleged infringement of four patents covering a fixed-combination formulation of brimonidine and timolol. After a four-day bench trial, the court found that each defendant's proposed product infringed the asserted claims (claim 4 of the '149 patent, claim 1 of the '976 patent, claims 1-6 of the '463 patent, and claims 1-9 of the '258 patent). The court further concluded that the patents-in-suit were not invalid, based on the trial evidence regarding the prior art, the unexpected efficacy of the combination, and the commercial success of the branded product.
The case involved a dispute over the priority of liens on property owned by Fred and Doris Neal, which had been transferred to a trust called Ultra Dimensions. The United States sought to foreclose federal tax liens for the Neals' tax liabilities, while Kenneth Goolsby claimed priority based on his earlier judgment lien against Fred Neal. The court ruled that the federal tax lien has priority over Goolsby's judgment lien. The core reasoning was that Goolsby's lien did not become choate under federal law until a court order in 2011 set aside the transfers, after the tax liens had already attached and been noticed.
The case involves a patent infringement suit by Dr. Saffran against Johnson & Johnson and Cordis over U.S. Patent No. 5,653,760, in which a jury found infringement, willfulness, and awarded $482 million in damages. Defendants raised a counterclaim of inequitable conduct, alleging that Saffran withheld material references to Dr. Langer's work and made misleading statements such as 'I have found' during patent prosecution. After a bench trial, the court ruled that defendants failed to prove inequitable conduct by clear and convincing evidence. The core reasoning was that no intent to deceive could be inferred from the withholding, given plausible explanations and lack of direct evidence, and that the references did not meet the materiality threshold under the reasonable examiner standard.
In Texas Data Co., LLC v. Target Brands, Inc., plaintiff Texas Data, a Texas company, filed a qui tam action under the false patent marking statute, 35 U.S.C. § 292, alleging that Target marked its up & up Training Pants with expired or inapplicable patents. The products were manufactured in Paris, Texas, and their packaging in Longview, Texas, both within the Eastern District of Texas, though some design and marking decisions occurred in Wisconsin. Target moved to transfer venue to the Eastern District of Wisconsin under 28 U.S.C. § 1404(a). The court denied the motion, holding that the balance of private and public interest factors did not show the proposed transferee venue to be clearly more convenient than the plaintiff's chosen forum.
This case is a patent infringement suit brought by Bruce N. Saffran against Johnson & Johnson and Cordis Corporation over U.S. Patent No. 5,653,760, which covers a flexible medical device for treating damaged tissue such as broken bones or blood vessels by restricting macromolecules and releasing treating materials. The court resolved multiple claim construction disputes under the standards from Markman and Phillips, examining the claims, specification, and prosecution history to determine the ordinary meaning of terms to a skilled artisan. Key constructions included defining "lysis of a chemical bond" as "breaking a chemical bond" based on the inventor's usage in the specification and distinguishing it from hydrolysis. The opinion adopts these definitions for use in the case while barring the parties from referencing their construction positions or the order itself before the jury.